ada standards of care 2025 obesity pharmacotherapy glp-1 agonists and changes in body mass and composition in adults with overweight or with or without type 2 diabetes mellitus: a systematic review and meta-analysis ADA 2025 Diabetes Management: CGM

Triple peptides for the treatment of obesity Retatrutide, a single peptide linked to a fatty diacid moiety, acts as a triple-agonist targeting three receptors: GIP, GLP-1, and glucagon

Neuroscience: The compound is used in studies investigating neuroprotective effects, particularly in conditions like stroke or neurodegenerative diseases, providing insights into therapeutic strategies

[68] Clinical trials have demonstrated the efficacy of albiglutide in lowering HbA1c levels and improving glycemic control

Bifidobacterium species, obligate anaerobes colonizing the distal small intestine and colon, support gut homeostasis by metabolizing dietary substrates, inhibiting pathogens, modulating inflammatory responses, maintaining barrier integrity, and contributing to micronutrient and bioactive compound production, with emerging evidence for antitumor potential (23, 24)